Citations

Showing 10 of 108036 citations.

Assessing Discomfort in American Adult Intensive Care Patients
Gunnels, Marshall S., Reisdorf, Emily M., Mandrekar, Jay , Chlan, Linda L.

Mayo Clinic

American Journal of Critical Care | March 1, 2024 | Volume: 33 | Issue: 2 | Pages: 126-132

10.4037/ajcc2024362 | PMID 38424019 Get It

Background While in the intensive care unit, critically ill patients experience a myriad of distressing symptoms and stimuli leading to discomfort, a negative emotional and/ or physical state that arises in response to noxious stimuli. Appropriate management of these symptoms requires a distinct assessment of discomfort-causing experiences. Objectives To assess patient-reported discomfort among critically ill patients with the English-language version of the Inconforts des Patients de REAnimation questionnaire, and to explore relationships between demographic and clinical characteristics and overall discomfort score on this instrument. Methods This study had a cross-sectional, descriptive, single-cohort design. The convenience sample consisted of alert and oriented patients aged 18 years or older who had been admitted to intensive care units at a Midwestern tertiary referral hospital and were invited to participate. An 18-item questionnaire on physiological and psychological stimuli inducing discomfort was administered once. Each item was scored from 0 to 10, with the total possible discomfort score ranging from 0 to 100. Descriptive statistics were used to analyze participants’ demographic and clinical characteristics and questionnaire responses. Results A total of 180 patients were enrolled. The mean (SD) overall discomfort score was 32.9 (23.6). The greatest sources of discomfort were sleep deprivation (mean [SD] score, 4.0 [3.4]), presence of perfusion catheters and tubing (3.4 [2.9]), thirst (3.0 [3.3]), and pain (3.0 [3.0]). Conclusions Intensive care unit patients in this study reported mild to moderate discomfort. Additional research is needed to design and test interventions based on assessment of specific discomfort-promoting stimuli to provide effective symptom management.
Patient experiences with prenatal cell‐free DNA screening in a safety net setting
Riggan, Kirsten A. , Barwise, Amelia , Yap, Jane Q. , Condon, Niamh, Allyse, Megan , Allyse, Megan A , Barwise, Amelia K , Riggan, Kirsten A , Yap, Jane Q

Mayo Clinic

Prenatal Diagnosis | March 1, 2024 | Volume: 44 | Issue: 4 | Pages: 409-417

10.1002/pd.6541 | PMID 38423995 Get It

AbstractObjectivesThirty‐five states, including Florida, now cover cell‐free DNA (cfDNA) screening of fetuses for all pregnant patients enrolled in state public insurance programs. We interviewed Black and Hispanic obstetric patients at a safety net clinic in Florida shortly after the state rolled out cfDNA as a first‐tier screening method for publicly insured patients.MethodsBlack and Hispanic patients receiving prenatal care from a prenatal or maternal fetal medicine clinic at a federally qualified health center in Jacksonville, FL were invited to participate in a qualitative interview in English or Spanish to explore experiences and perceptions of prenatal cfDNA screening. Participants were recruited following their first prenatal visit when cfDNA is typically introduced. Interview transcripts were qualitatively analyzed for iterative themes based on principles of grounded theory.ResultsOne hundred Black and Hispanic patients (n = 51 non‐Hispanic Black, n = 43 Hispanic, n = 3 Hispanic Black, n = 3 Not Reported/Other) completed an interview. Participants described minimal opportunity for pre‐screening counseling and limited health literacy about cfDNA or its uses. Some believed that cfDNA could positively impact pregnancy health. Many were unsure if they had received cfDNA even though they were aware of the information provided by it. Most participants expressed an interest in cfDNA as a means for early detection of fetal sex and as an additional indication of general fetal health.ConclusionsPatient experiences indicate limited informed consent and decision‐making for cfDNA, discordant with professional guidelines on pre‐screen counseling. Our findings suggest that there should be additional investment in implementing cfDNA in safety net settings to ensure that patients and providers receive the support necessary for effective patient counseling and follow‐on care for the ethical implementation of cfDNA.
Metal artifact reduction sequence-MRI abnormalities in asymptomatic patients with dual-mobility hip prostheses
Chung, Brian , Liu, Kevin C. , Chen, Xiao T. , Lovro, Luke R. , Kistler, Natalie M. , Longjohn, Donald B. , Oakes, Daniel A. , Lieberman, Jay R. , Lovro, Luke R , Heckmann, Nathanael D. , White, Eric A. , Christ, Alexander B.

Mayo Clinic

The Bone & Joint Journal | March 1, 2024 | Volume: 106-B | Issue: 3 Supple A | Pages: 89-96

10.1302/0301-620x.106b3.bjj-2023-0643.r1 | PMID 38423076 Get It

AimsModular dual-mobility (DM) articulations are increasingly used during total hip arthroplasty (THA). However, concerns remain regarding the metal liner modularity. This study aims to correlate metal artifact reduction sequence (MARS)-MRI abnormalities with serum metal ion levels in patients with DM articulations.MethodsA total of 45 patients (50 hips) with a modular DM articulation were included with mean follow-up of 3.7 years (SD 1.2). Enrolled patients with an asymptomatic, primary THA and DM articulation with over two years’ follow-up underwent MARS-MRI. Each patient had serum cobalt, chromium, and titanium levels drawn. Patient satisfaction, Oxford Hip Score, and Forgotten Joint Score-12 (FJS-12) were collected. Each MARS-MRI was independently reviewed by fellowship-trained musculoskeletal radiologists blinded to serum ion levels.ResultsOverall, two patients (4.4%) had abnormal periprosthetic fluid collections on MARS-MRI with cobalt levels > 3.0 μg/l. Four patients (8.9%) had MARS-MRI findings consistent with greater trochanteric bursitis, all with cobalt levels < 1.0 μg/l. A seventh patient had a periprosthetic fluid collection with normal ion levels. Of the 38 patients without MARS-MRI abnormalities, 37 (97.4%) had cobalt levels < 1.0 μg/l, while one (2.6%) had a cobalt level of 1.4 μg/l. One patient (2.2%) had a chromium level > 3.0 μg/l and a periprosthetic fluid collection. Of the 41 patients with titanium levels, five (12.2%) had titanium levels > 5.0 μg/l without associated MARS-MRI abnormalities.ConclusionPeriprosthetic fluid collections associated with elevated serum cobalt levels in patients with asymptomatic DM articulations occur infrequently (4.4%), but further assessment is necessary due to implant heterogeneity.Cite this article: Bone Joint J 2024;106-B(3 Supple A):89–96.
The International Hip Society Supplement Part I: current controversies in total hip arthroplasty
Haddad, Fares S. , Berry, Daniel J. , Berry, Daniel J

Mayo Clinic

The Bone & Joint Journal | March 1, 2024 | Volume: 106-B | Issue: 3 Supple A | Pages: 1-2

10.1302/0301-620x.106b3.bjj-2024-0135 | PMID 38423089 Get It

Enhanced recovery protocols after surgery: A systematic review and meta‐analysis of randomized trials in cardiac surgery
Spadaccio, Cristiano , Salsano, Antonio , Pisani, Angelo , Nappi, Francesco , D’Alessandro, David A. , Sundt, Thoralf M. , Nappi, Francesco , Nenna, Antonio , Osho, Asishana A. , Crestanello, Juan A. , Engelman, Daniel T. , Rose, David

Mayo Clinic

World Journal of Surgery | February 29, 2024 | Volume: 48 | Issue: 4 | Pages: 779-790

10.1002/wjs.12122 | PMID 38423955 Get It

Abstract Background Previous meta‐analyses combining randomized and observational evidence in cardiac surgery have shown positive impact of enhanced recovery protocols after surgery (ERAS) on postoperative outcomes. However, definitive data based on randomized studies are missing, and the entirety of the ERAS measures and pathway, as recently systematized in guidelines and consensus statements, have not been captured in the published studies. The available literature actually focuses on “ERAS‐like” protocols or only limited number of ERAS measures. This study aims at analyzing all randomized studies applying ERAS‐like protocols in cardiac surgery for perioperative outcomes. Methods A meta‐analysis of randomized controlled trials (RCTs) comparing ERAS‐like with standard protocols of perioperative care was performed (PROSPERO registration CRD42021283765). PRISMA guidelines were used for abstracting and assessing data. Results Thirteen single center RCTs ( N = 1704, 850 in ERAS‐like protocol and 854 in the standard care group) were selected. The most common procedures were surgical revascularization (66.3%) and valvular surgery (24.9%). No difference was found in the incidence of inhospital mortality between the ERAS and standard treatment group (risk ratio [RR] 0.61 [0.31; 1.20], p = 0.15). ERAS was associated with reduced intensive care unit (standardized mean difference [SMD] −0.57, p < 0.01) and hospital stay (SMD −0.23, p < 0.01) and reduced rates of overall complications when compared to the standard protocol (RR 0.60, p < 0.01) driven by the reduction in stroke (RR 0.29 [0.13; 0.62], p < 0.01). A significant heterogeneity in terms of the elements of the ERAS protocol included in the studies was observed. Conclusions ERAS‐like protocols have no impact on short‐term survival after cardiac surgery but allows for a faster hospital discharge while potentially reducing surgical complications. However, this study highlights a significant nonadherence and heterogeneity to the entirety of ERAS protocols warranting further RCTs in this field including a greater number of elements of the framework.
Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey
Yoshida, Akira , Maroufy, Vahed , Kuwana, Masataka , Shaharir, Syahrul Sazliyana , Kadam, Esha , Goo, Phonpen Akawatcharangura , Milchert, Marcin , Dey, Dzifa , Velikova, Tsvetelina , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Ziadé, Nelly , Kibbi, Lina El, Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Kardeş, Sinan , Vince, Melinda Nagy, Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal, Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Vaidya, Binit , Yıldırım, Reşit, Atzeni, Fabiola , Bocci, Elena Bartoloni, Orsolini, Giovanni , Angelis, Rossella De , Giollo, Alessandro, Fornaro, Marco, González, Raquel , Nakashima, Ran , Sato, Shinji , Kimura, Naoki , Kaneko, Yuko , Gono, Takahisa , Tomaras, Stylianos, Aharonov, Or, Bouchti, I. El , Baba, Zineb, Maurier, F. , Meyer, Alain, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Harifi, Ghita, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, Nunez, Lilith Stange, Vergara, Cristián, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Mendoza, Idania Escalante, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Patel, Aarat , Tehozol, Erick Adrian Zamora , Chalico, Javier Merayo, Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Hasan, A T M Tanveer , Salim, Babur , Gupta, Latika , Kuwana, Masataka , Lilleker, James B , Day, Jessica , Milchert, Marcin , Dey, Dzifa , Gracia-Ramos, Abraham Edgar , Parodis, Ioannis , Tan, Ai Lyn , Nune, Arvind , Ziade, Nelly , Knitza, Johannes , Distler, Oliver , Chinoy, Hector , Aggarwal, Rohit , Gupta, Latika , Agarwal, Vikas , Velikova, Tsvetelina , Zamora Tehozol, Erick Adrian , Caballero-Uribe, Carlo Vinicio , Yoshida, Akira , De Angelis, Rossella , Li, Yuan , Makol, Ashima , Sen, Parikshit , Agarwal, Vishwesh , Day, Jessica , Chen, Yi‐Ming , Saha, Sreoshy , Gracia‐Ramos, Abraham Edgar , Nune, Arvind , Cavagna, Lorenzo , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study, Griger, Zoltán , Singh, Yogesh Preet , Ranjan, Rajiv , Jain, Avinash , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Ajmani, Sajal , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Sambataro, Gianluca , Govoni, Marcello , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Danieli, Maria Giovanna , Venerito, Vincenzo , Grignaschi, Silvia , Giollo, Alessandro, Alunno, Alessia , Iannone, Florenzo , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Loarce‐Martos, Jesus , Prieto‐González, Sergio , Gonzalez, Raquel Aranega, Tomaras, Stylianos , Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Baba, Zineb, Giannini, Margherita , Campagne, Julien , Meyer, Alain , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Arbeláez-Cortés, Álvaro , Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Doskaliuk, Bohdana , Emorinken, Airenakho , Olaosebikan, Hakeem , Ugarte‐Gil, Manuel F. , Mohammed, Reem Hamdy A , Harifi, Ghita , Fuentes-Silva, Yurilís , Salinas, Rodrigo Nicolás Garcia , Andréoli, Laura , Lini, Daniele , Schreiber, Karen , Pauling, John D , Wincup, Chris , Barman, Bhupen , Rojas Serrano, Jorge , Torre, Ignacio García-De La, Colunga-Pedraza, I. J. , Shumnalieva, Russka , Hoff, Leonardo Santos , Halabi, Hussein , Gheita, Tamer A. , Chatterjee, Tulika

Mayo Clinic

Rheumatology Advances in Practice | February 29, 2024 | Volume: 8 | Issue: 2 | Pages: No page available

10.1093/rap/rkae028 | PMID 38524696 Get It

Abstract Objectives To investigate health-related quality of life in patients with idiopathic inflammatory myopathies (IIMs) compared with those with non-IIM autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs) and without autoimmune diseases (controls) using Patient-Reported Outcome Measurement Information System (PROMIS) instrument data obtained from the second COVID-19 vaccination in autoimmune disease (COVAD-2) e-survey database. Methods Demographics, diagnosis, comorbidities, disease activity, treatments and PROMIS instrument data were analysed. Primary outcomes were PROMIS Global Physical Health (GPH) and Global Mental Health (GMH) scores. Factors affecting GPH and GMH scores in IIMs were identified using multivariable regression analysis. Results We analysed responses from 1582 IIM, 4700 non-IIM AIRD and 545 nrAID patients and 3675 controls gathered through 23 May 2022. The median GPH scores were the lowest in IIM and non-IIM AIRD patients {13 [interquartile range (IQR) 10–15] IIMs vs 13 [11–15] non-IIM AIRDs vs 15 [13–17] nrAIDs vs 17 [15–18] controls, P &lt; 0.001}. The median GMH scores in IIM patients were also significantly lower compared with those without autoimmune diseases [13 (IQR 10–15) IIMs vs 15 (13–17) controls, P &lt; 0.001]. Inclusion body myositis, comorbidities, active disease and glucocorticoid use were the determinants of lower GPH scores, whereas overlap myositis, interstitial lung disease, depression, active disease, lower PROMIS Physical Function 10a and higher PROMIS Fatigue 4a scores were associated with lower GMH scores in IIM patients. Conclusion Both physical and mental health are significantly impaired in IIM patients, particularly in those with comorbidities and increased fatigue, emphasizing the importance of patient-reported experiences and optimized multidisciplinary care to enhance well-being in people with IIMs.
Cone-Beam CT of the Extremities in Clinical Practice
Doan, Matthew K. , Long, Jeremiah R. , Verhey, Erik M., Wyse, Aaron , Flug, Jonathan A. , Verhey, Erik, Flug, Jonathan A , Long, Jeremiah , Patel, Karan A.

Mayo Clinic

RadioGraphics | February 29, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1148/rg.230143 | PMID 38421913 Get It

MRI in Adult Patients with Active and Inactive Implanted MR-conditional, MR-nonconditional, and Other Devices
Harwood, Matthew , Fahrenholtz, Samuel J. , Wellnitz, Clinton V., Kawashima, Akira , Panda, Anshuman , Kawashima, Akira , Harwood, Matthew

Mayo Clinic

RadioGraphics | February 29, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1148/rg.230102 | PMID 38421911 Get It

Automated target placement for VMAT lattice radiation therapy: enhancing efficiency and consistency
Deufel, Christopher L. , Kavanaugh, James , Finley, Randi R., Lang, Karen , Sorenson, Kasie L., Spreiter, Sheri M., Brooks, Jamison , Haddock, Michael G. , Petersen, Ivy A. , Owen, Dawn, Deufel, Christopher, Finley, Randi, Sorenson, Kasie, Spreiter, Sheri, Moseley, Douglas, Ahmed, Safia K. , Owen, Dawn W, Brooks, Jamison , Dodoo, Christopher , Moseley, D , Daniel, J. , Park, Sean S. , Grams, Michael P.

Mayo Clinic

Physics in Medicine & Biology | February 29, 2024 | Volume: 69 | Issue: 7 | Pages: 075010

10.1088/1361-6560/ad2ee8 | PMID 38422544 Get It

Abstract Objective . An algorithm was developed for automated positioning of lattice points within volumetric modulated arc lattice radiation therapy (VMAT LRT) planning. These points are strategically placed within the gross tumor volume (GTV) to receive high doses, adhering to specific separation rules from adjacent organs at risk (OARs). The study goals included enhancing planning safety, consistency, and efficiency while emulating human performance. Approach . A Monte Carlo-based algorithm was designed to optimize the number and arrangement of lattice points within the GTV while considering placement constraints and objectives. These constraints encompassed minimum spacing between points, distance from OARs, and longitudinal separation along the z -axis. Additionally, the algorithm included an objective to permit, at the user’s discretion, solutions with more centrally placed lattice points within the GTV. To validate its effectiveness, the automated approach was compared with manually planned treatments for 24 previous patients. Prior to clinical implementation, a failure mode and effects analysis (FMEA) was conducted to identify potential shortcomings. Main results. The automated program successfully met all placement constraints with an average execution time (over 24 plans) of 0.29 ±0.07 min per lattice point. The average lattice point density (# points per 100 c.c. of GTV) was similar for automated (0.725) compared to manual placement (0.704). The dosimetric differences between the automated and manual plans were minimal, with statistically significant differences in certain metrics like minimum dose (1.9% versus 1.4%), D5% (52.8% versus 49.4%), D95% (7.1% versus 6.2%), and Body-GTV V30% (20.7 c.c. versus 19.7 c.c.). Significance. This study underscores the feasibility of employing a straightforward Monte Carlo-based algorithm to automate the creation of spherical target structures for VMAT LRT planning. The automated method yields similar dose metrics, enhances inter-planner consistency for larger targets, and requires fewer resources and less time compared to manual placement. This approach holds promise for standardizing treatment planning in prospective patient trials and facilitating its adoption across centers seeking to implement VMAT LRT techniques.
Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations
Møller, Pål , McCuaig, Jeanna , Eisen, Andrea , Bordeleau, Louise , Zakalik, Dana , Metcalfe, Kelly , Olopade, Olufunmilayo I. , Sun, Ping , Narod, Steven A. , Sweet, Kevin , Elser, Christine , Wiesner, Georgia L. , Poll, Aletta, Kim, Raymond H. , Armel, Susan T., Demsky, Rochelle, Serfas, Kim, Panchal, Seema, Cullinane, Carey A., Reilly, Robert E., Mercer, L J, Dungan, J.S., Lemire, Edmond G., Zovato, Stefania , Rastelli, Antonella, Olopade, Olufunmilayo I , Metcalfe, Kelly A , Eisen, Andrea , Bordeleau, Louise , Kim, Raymond H , Kotsopoulos, Joanne , Gronwald, Jacek , Huzarski, Tomasz , Pal, Tuya , Singer, Christian F. , Karlan, Beth Y. , Aeilts, Amber M. , Eng, Charis , Foulkes, William D. , Tung, Nadine , Couch, Fergus J. , Fruscio, Robert , Neuhausen, Susan L. , Cybulski, Cezary , Lubiński, Jan , Armel, Susan, Steele, Linda, Saal, Howard M. , Rayson, Daniel , Mercer, Leanne, Cajal, Teresa Ramón y , Cohen, Stephanie A.

Mayo Clinic

JAMA Oncology | February 29, 2024 | Volume: 10 | Issue: 4 | Pages: 484

10.1001/jamaoncol.2023.6937 | PMID 38421677 Get It

ImportancePreventive bilateral salpingo-oophorectomy is offered to women at high risk of ovarian cancer who carry a pathogenic variant in BRCA1 or BRCA2; however, the association of oophorectomy with all-cause mortality has not been clearly defined.ObjectiveTo evaluate the association between bilateral oophorectomy and all-cause mortality among women with a BRCA1 or BRCA2 sequence variation.Design, Setting, and ParticipantsIn this international, longitudinal cohort study of women with BRCA sequence variations, information on bilateral oophorectomy was obtained via biennial questionnaire. Participants were women with a BRCA1 or BRCA2 sequence variation, no prior history of cancer, and at least 1 follow-up questionnaire completed. Women were followed up from age 35 to 75 years for incident cancers and deaths. Cox proportional hazards regression was used to estimate the hazard ratios (HRs) and 95% CIs for all-cause mortality associated with a bilateral oophorectomy (time dependent). Data analysis was performed from January 1 to June 1, 2023.ExposuresSelf-reported bilateral oophorectomy (with or without salpingectomy).Main Outcomes and MeasuresAll-cause mortality, breast cancer–specific mortality, and ovarian cancer–specific mortality.ResultsThere were 4332 women (mean age, 42.6 years) enrolled in the cohort, of whom 2932 (67.8%) chose to undergo a preventive oophorectomy at a mean (range) age of 45.4 (23.0-77.0) years. After a mean follow-up of 9.0 years, 851 women had developed cancer and 228 had died; 57 died of ovarian or fallopian tube cancer, 58 died of breast cancer, 16 died of peritoneal cancer, and 97 died of other causes. The age-adjusted HR for all-cause mortality associated with oophorectomy was 0.32 (95% CI, 0.24-0.42; P &amp;lt; .001). The age-adjusted HR was 0.28 (95% CI, 0.20-0.38; P &amp;lt; .001) and 0.43 (95% CI, 0.22-0.90; P = .03) for women with BRCA1 and BRCA2 sequence variations, respectively. For women with BRCA1 sequence variations, the estimated cumulative all-cause mortality to age 75 years for women who had an oophorectomy at age 35 years was 25%, compared to 62% for women who did not have an oophorectomy. For women with BRCA2 sequence variations, the estimated cumulative all-cause mortality to age 75 years was 14% for women who had an oophorectomy at age 35 years compared to 28% for women who did not have an oophorectomy.Conclusions and RelevanceIn this cohort study among women with a BRCA1 or BRCA2 sequence variation, oophorectomy was associated with a significant reduction in all-cause mortality.